Abcellera Biologics INC

AbCellera Biologics Inc. announced a strategic collaboration with Vertex Pharmaceuticals Incorporated to discover, develop, and commercialize multispecific T-cell engagers for autoimmune diseases.

AbCellera Biologics Inc. announced the appointment of Dr. Lynn Seely as an independent director to its Board of Directors.

AbCellera Biologics Inc. and Jazz Pharmaceuticals plc have entered into a preclinical research collaboration to discover and develop next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors.

AbCellera Biologics shareholders re-elected Class III directors and ratified the appointment of Ernst & Young LLP.

AbCellera Biologics Inc. has appointed veteran medical oncologist Dr. Victor Sandor as an independent director to its Board of Directors.

AbCellera Biologics Inc. announced its Q1 2026 financial results and positive interim Phase 1 data for its potential first-in-class antibody, ABCL635, targeting the neurokinin 3 receptor for menopausal vasomotor symptoms.

AbCellera Biologics Inc. reported its first quarter 2026 financial results, highlighting increased revenue and progress in its internal drug candidate pipeline, particularly with ABCL635.

AbCellera Biologics reported increased revenue but a wider net loss in Q3 2025, while advancing two antibody therapies into Phase 1 clinical trials and a third into IND/CTA-enabling studies.

AbCellera Biologics reports reduced operating losses and significant clinical pipeline advancements, initiating Phase 1 trials for two antibody therapies while maintaining a strong liquidity position.

AbCellera Biologics' Q1 2025 revenue decreased due to a shift towards internal programs, while R&D expenses increased as the company advances its pipeline.

AbCellera Biologics Inc. reported a net loss of $51.1 million for the third quarter of 2024, with revenue decreasing slightly and operating expenses increasing significantly due to impairment charges.

AbCellera Biologics Inc. reported a decrease in revenue for the second quarter of 2024, alongside increased operating expenses primarily driven by research and development and a significant impairment charge.

AbCellera Biologics Inc. reported a 161% revenue increase and reduced net loss in 2025, driven by a patent settlement and clinical pipeline advancements.

AbCellera Biologics Inc. files its annual report on Form 10-K, highlighting its focus on antibody drug discovery and development, advancements in its internal programs, and strategic partnerships.

AbCellera Biologics Inc.'s 2023 annual report details strategic investments in technology and internal programs, alongside a diversified partnership portfolio, while navigating a shift from COVID-19 related revenues.

Director Lynn Seely of AbCellera Biologics Inc. acquired stock options, with vesting scheduled over three years.

Victor Sandor, a Director at AbCellera Biologics Inc., has acquired stock options as part of his compensation, with vesting over three years.

Director Michael R. Hayden was granted 111,701 stock options in AbCellera Biologics Inc. as part of standard compensation.

Director Stephen Quake was granted options to purchase 111,701 common shares of AbCellera Biologics Inc. on June 11, 2026.

Director John S. Montalbano was granted 111,701 stock options in AbCellera Biologics Inc. as part of an equity incentive.

Andrew Booth, Chief Financial Officer of AbCellera Biologics Inc., reported a transaction involving the acquisition of 250,000 common shares.

AbCellera Biologics Inc. has announced its 2026 Annual Meeting of Shareholders will be held virtually on June 11, 2026, to elect directors, ratify auditor appointment, and vote on executive compensation.

AbCellera Biologics Inc. will hold its annual meeting of stockholders on June 12, 2025, to elect directors, ratify the appointment of KPMG LLP as the independent auditor, and conduct an advisory vote on executive compensation.

AbCellera Biologics Inc. will hold its 2025 Annual Meeting of Shareholders virtually on June 12, 2025, to elect directors, ratify the appointment of KPMG LLP, and conduct a non-binding advisory vote on executive compensation.

AbCellera Biologics Inc. will hold its annual meeting of stockholders on June 13, 2024, to elect directors, ratify the appointment of KPMG LLP, and approve executive compensation.

AbCellera Biologics will hold its 2024 Annual Meeting of Shareholders virtually on June 13, 2024, to vote on director elections, auditor ratification, and executive compensation.